Chemocentryx Inc’s (NASDAQ:CCXI) Sentiment is 1.59

ChemoCentryx, Inc. (NASDAQ:CCXI) Logo

Sentiment for Chemocentryx Inc (NASDAQ:CCXI)

Chemocentryx Inc (NASDAQ:CCXI) institutional sentiment increased to 1.59 in Q2 2018. Its up 0.59, from 1 in 2018Q1. The ratio is better, as 62 institutional investors opened new or increased stock positions, while 39 decreased and sold their holdings in Chemocentryx Inc. The institutional investors in our partner’s database now possess: 26.37 million shares, up from 24.22 million shares in 2018Q1. Also, the number of institutional investors holding Chemocentryx Inc in their top 10 stock positions was flat from 1 to 1 for the same number . Sold All: 11 Reduced: 28 Increased: 34 New Position: 28.

ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, develops medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. The company has market cap of $497.68 million. The Company’s lead drug candidate is Avacopan , an orally-administered small molecule that is a selective inhibitor of the complement C5a receptor (C5Ar), which is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis (AAV). It has a 39.88 P/E ratio. The firm also engages in developing CCX140, an inhibitor of the chemokine receptor known as CCR2 for patients with focal segmental glomerulosclerosis (FSGS), a debilitating kidney disease; Vercirnon for the treatment of patients with moderate-to-severe CrohnÂ’s diseases; CCX872, a selective inhibitor of the human CCR2 that has completed Phase I clinical trial for the treatment of pancreatic cancer; CCX507, which has completed Phase I clinical trial for the treatment of inflammatory bowel diseases; and Th17 cells for the treatment of psoriasis, rheumatoid arthritis, asthma, and multiple sclerosis.

The stock decreased 3.62% or $0.37 during the last trading session, reaching $9.85. About 213,959 shares traded. ChemoCentryx, Inc. (NASDAQ:CCXI) has risen 51.30% since December 8, 2017 and is uptrending. It has outperformed by 35.68% the S&P500.

Analysts await ChemoCentryx, Inc. (NASDAQ:CCXI) to report earnings on March, 8. They expect $-0.27 EPS, down 133.75 % or $1.07 from last year’s $0.8 per share. After $-0.22 actual EPS reported by ChemoCentryx, Inc. for the previous quarter, Wall Street now forecasts 22.73 % negative EPS growth.

Bvf Inc Il holds 9.04% of its portfolio in ChemoCentryx, Inc. for 7.03 million shares. P.A.W. Capital Corp owns 85,000 shares or 1.13% of their US portfolio. Moreover, Wasatch Advisors Inc has 0.38% invested in the company for 2.38 million shares. The Connecticut-based Nantahala Capital Management Llc has invested 0.33% in the stock. Spark Investment Management Llc, a New York-based fund reported 163,900 shares.

Since January 1, 0001, it had 0 insider buys, and 7 selling transactions for $88.11 million activity.

ChemoCentryx, Inc. (NASDAQ:CCXI) Ratings Coverage

Ratings analysis reveals 50% of ChemoCentryx’s analysts are positive. Out of 4 Wall Street analysts rating ChemoCentryx, 2 give it “Buy”, 0 “Sell” rating, while 2 recommend “Hold”. The lowest target is $12.5 while the high is $20. The stock’s average target of $16.38 is 66.29% above today’s ($9.85) share price. CCXI was included in 4 notes of analysts from June 28, 2018. As per Monday, November 12, the company rating was maintained by Canaccord Genuity. JP Morgan downgraded the stock to “Neutral” rating in Tuesday, August 14 report.

More notable recent ChemoCentryx, Inc. (NASDAQ:CCXI) news were published by: Seekingalpha.com which released: “Premarket analyst action – healthcare – Seeking Alpha” on September 07, 2018, also Seekingalpha.com with their article: “Investors returning to tiny biotechs – Seeking Alpha” published on November 16, 2018, Nasdaq.com published: “ChemoCentryx’s Novel Small Molecule Antagonists of Checkpoint Inhibitors and Chemokine Receptors to be Presented at the American Association for Cancer Research (AACR) Tumor Immunology and Immunotherapy Conference – Nasdaq” on November 29, 2018. More interesting news about ChemoCentryx, Inc. (NASDAQ:CCXI) were released by: Globenewswire.com and their article: “ChemoCentryx Reports Second Quarter 2018 Financial Results and Recent Highlights – GlobeNewswire” published on August 09, 2018 as well as Nasdaq.com‘s news article titled: “Health Care Sector Update for 09/28/2018: SPRO, CCXI, ALDX – Nasdaq” with publication date: September 28, 2018.

ChemoCentryx, Inc. (NASDAQ:CCXI) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.